




www.colloquium2019.org.za









**TARIRO FINANCIAL SERVICES (PTY) LTD** 


## **IMPAIRED LIVES INSURABILITY:**

### DAWN OF A NEW ERA





AGENDA




- Explore the nature of longevity improvements
- History and milestones of longevity improvements

SECTION

- Implications
- Applications
  - Impaired life insurance








## What is the need that we seek to address










- By cause of death
- By age ranges at which improvements take place





### NATURE OF LONGEVITY IMPROVEMENTS: Alternative view



• Analyse improvements into two parts


Changes in disease-specific incidence rates

Changes in survival rates of those afflicted by these


diseases







#### **Progression of illness**




SECTION




C O L L O Q U I U M 2 O I 9





#### **Progression of illness**



-----Incurable lethal illness


SECTION



019

C O L L O Q II I II M 7







Hosted by

019

#### **Progression of illness**








Hosted by


SOCIE'I

019

#### **Progression of illness**








Hosted by


SOCIET

019

#### **Progression of illness**








## EXAMPLES OF LETHAL CONDITIONS TURNED CHRONIC:

#### **PROSTATE CANCER AND BREAST CANCER**






**PROSTATE CANCER** 





019





#### **PROSTATE CANCER**






5-year relative survival %




Hosted by



#### **PROSTATE CANCER**






Deaths per 100 patients, 5 years after diagnosis




Hosted by



**BREAST CANCER** 











#### **BREAST CANCER**











Hosted by ACTUARIAL



#### **BREAST CANCER**






**Source: SEER** 



Hosted by ACTUARIAL SOCIETY






### **IMPLICATIONS & APPLICATIONS**







- Prohibitive cost of cancer treatment due to
  - Substantial increase in treatment cost per case AND
  - Increase in proportion of population with cancer


- Biologics can easily cost over \$400 000 per course
- Even 3rd party payers (Insurers, Governments) are now passing on an increasing share of burden back to patients

SECTIO

Result is financial toxicity








### CANCER TREATMENT FINANCE INSTRUMENT








## What is the need that we seek to address





Swap instrument




- Changes nature of treatment payment obligation
- From liability for treatment to liability for <u>successful</u> treatment
- Basic measure of success is survival





Swap instrument



### • Other measures can be used as well-

Cancer remission

➤and thereafter remaining cancer free


- ➤ Metastasis
- ≻Relapse
- Referred to as Outcomes-based reimbursement models ('OBM')

SECTION

As opposed to conventional Fee-For Service ('FFS') models








# CANCER TREATMENT


# FINANCE SWAP








# Conventional monetary flows











## Monetary flows under swap








## WHY NOW?

Private & Confidential






- ✓ Loss event must be well defined, and unambiguous;
- ✓ Events must be independent of each other
- Arrangement must not be susceptible to moral hazard;
- x Arrangement must not be susceptible to anti-selection
- x Mortality rates must be forecastable with degree of certainty
- x Possible loss must be substantial
- x Low Likelihood of a loss









- Arrangement are susceptible to anti-selection:
  - Information asymmetry no longer so stark. Objective clinical measures of severity of malignancy
- Mortality not forecastable with degree of certainty
  - Rich databases of cancer morbidity and mortality also now available
- Likelihood of a loss NOT low
  - Much lower probabilities of loss
- Possible loss NOT substantial
  - Losses ARE NOW substantial






#### Why Cancer?












- For patient/family-mitigates financial toxicity, even averting bankruptcy
- For patient/family-Easier to secure treatment financing and on favourable terms. Improves clinical outcomes
- For treating physician-strengthens guarantee of payment for services.
- For treating physician- Reduces constraints on selection of optimal treatment options








# PARENTAL SUPPORT COVER






Longevity implications



- Longevity primarily responsible for pensions crisis
- Compounded by shift from DB to DC
- Responsibility for pensioner support falling back to adult children (often middle aged themselves)
- Cost of support exacerbated by soaring medical costs








- This gives rise to an insurable interest for middle aged people with elderly parents
- If they support these parents there is a risk that they pre-decease them
- This risk can be mitigated by life insurance.
- Insurable risk even if the insured life is impairedrisk of deceasing parent may still be low enough to be insurable

SECTION





CONCLUSION



# #ImpairedLivesMatter

